韓国のがん疼痛管理市場予測　2024-2032年

Report Overview

KEY FINDINGS
The South Korea cancer pain management market is anticipated to develop with a CAGR of 5.92% during the forecast period 2024-2032.

韓国のがん疼痛管理市場は、2024年から2032年の予測期間中に5.92%のCAGRで発展すると予想されています。

MARKET INSIGHTS
According to the Korean Cancer Association, an estimated 273,076 new cancer cases and 81,818 cancer deaths were expected in Korea in 2023. The most common cancer types include thyroid, lung, breast, rectum, colon, and stomach cancers, which together account for half of the overall cancer burden in the country. Lung cancer is anticipated to be the leading cause of cancer-related deaths, followed by liver, colorectal, pancreatic, and gallbladder cancers.
Growing cancer prevalence and enhanced government support for cancer care have significantly influenced the cancer pain management market in South Korea. Each year, between 10,000 and 20,000 individuals are diagnosed with cancer. Advances in diagnostic tools and pharmaceutical developments have increased the number of cancer survivors and improved their 5-year relative survival rates. This growing population of survivors underscores the need for effective pain management solutions to improve their quality of life.
Additionally, South Korea is experiencing rapid population aging, with a significant increase in the number of elderly individuals. According to World Bank data, in 2022, the total population aged 65 and above was 9,030,344 in South Korea. As older adults are more susceptible to cancer, this demographic shift further drives the demand for comprehensive cancer pain management solutions. The rising incidence of cancer among the elderly necessitates specialized pain management approaches to meet their unique needs.
Innovations in palliative care are crucial to the cancer pain management market in South Korea. The development and implementation of advanced hospice palliative care (HPC) services, including policy changes that allow terminally ill patients to refuse life-sustaining treatments, highlight the country’s commitment to improving end-of-life care. These advancements in cancer treatment aim to enhance the quality of life for cancer patients by addressing their physical, emotional, and spiritual needs.

REPORT SYNOPSIS

SEGMENTATION ANALYSIS
The report on the South Korea cancer pain management market includes the segmentation analysis based on drug type and disease indication.

Market by Drug Type:
• Opioids
• Morphine
• Fentanyl
• Other Morphines
• Non-Opioids
• Acetaminophen
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
• Nerve Blockers
Market by Disease Indication:
• Lung Cancer
• Colorectal Cancer
• Breast Cancer
• Prostate Cancer
• Blood Cancer
• Other Disease Indications
Inkwood Research’s report on the South Korea cancer pain management market provides in-depth insights as well as the market’s segmentation analysis. The detailed evaluation of the market includes Competitive Landscape and Value Chain Analysis.

COMPETITIVE ANALYSIS
Key players operating in the South Korea cancer pain management market include Daiichi Sankyo Company Ltd, Pfizer, Teva Pharmaceutical Industries Limited, Mundipharma International, Hanmi Pharmaceutical Co, etc.
Teva Pharmaceutical Industries Limited, founded in 1901 and headquartered in Tel Aviv, Israel, is a global pharmaceutical company that produces a variety of medicines and biopharmaceutical products. The company specializes in cytotoxic substances, sterile products, hormones, and high-potency drugs. Teva offers medications in multiple forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It focuses on therapeutic areas such as respiratory, central nervous system (CNS), pain, and oncology. Teva operates in North America, Europe, Israel, and other international markets.

Table of Contents

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. COUNTRY SNAPSHOT — SOUTH KOREA
2.3. COUNTRY ANALYSIS — SOUTH KOREA
2.4. SCOPE OF STUDY
2.5. CRISIS SCENARIO ANALYSIS
2.5.1. IMPACT OF COVID-19 ON THE SOUTH KOREA CANCER PAIN MANAGEMENT MARKET
2.6. MAJOR MARKET FINDINGS
2.6.1. INNOVATIONS IN PALLIATIVE CARE
2.6.2. SURGE IN PERSONALIZED MEDICINE APPROACHES
2.6.3. EXPANSION OF SPECIALIZED CANCER CARE FACILITIES
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. INCREASING PREVALENCE OF CANCER IN SOUTH KOREA
3.1.2. SURGE IN GERIATRIC POPULATION
3.1.3. ADVANCED HEALTHCARE INFRASTRUCTURE
3.2. KEY RESTRAINTS
3.2.1. REGULATORY CHALLENGES AND APPROVAL DELAYS
3.2.2. HIGH COST OF TREATMENT
3.2.3. OPIOID SIDE EFFECTS AND ADDICTION CONCERNS
4. KEY ANALYTICS
4.1. KEY MARKET TRENDS
4.1.1. ADVANCEMENTS IN MEDICAL TECHNOLOGY IN SOUTH KOREA
4.1.2. SUPPORTIVE GOVERNMENT POLICIES FOR CANCER PAIN MANAGEMENT
4.1.3. ACTIVE R&D BY PHARMACEUTICAL COMPANIES
4.2. PESTLE ANALYSIS
4.2.1. POLITICAL
4.2.2. ECONOMICAL
4.2.3. SOCIAL
4.2.4. TECHNOLOGICAL
4.2.5. LEGAL
4.2.6. ENVIRONMENTAL
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTIONS
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING — SOUTH KOREA
4.5. VALUE CHAIN ANALYSIS
4.5.1. RESEARCH & DEVELOPMENT
4.5.2. REGULATORY APPROVAL
4.5.3. MANUFACTURING
4.5.4. DISTRIBUTION
4.5.5. END-USERS
5. MARKET BY DRUG TYPE
5.1. OPIOIDS
5.2. MORPHINE
5.2.1. FENTANYL
5.2.2. OTHER MORPHINES
5.3. NON-OPIOIDS
5.4. ACETAMINOPHEN
5.5. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
5.6. NERVE BLOCKERS
6. MARKET BY DISEASE INDICATION
6.1. LUNG CANCER
6.2. COLORECTAL CANCER
6.3. BREAST CANCER
6.4. PROSTATE CANCER
6.5. BLOOD CANCER
6.6. OTHER DISEASE INDICATIONS
7. COMPETITIVE LANDSCAPE
7.1. KEY STRATEGIC DEVELOPMENTS
7.1.1. MERGERS & ACQUISITIONS
7.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
7.1.3. PARTNERSHIPS & AGREEMENTS
7.1.4. BUSINESS EXPANSIONS & DIVESTITURES
7.2. COMPANY PROFILES
7.2.1. DAIICHI SANKYO COMPANY LIMITED
7.2.1.1. COMPANY OVERVIEW
7.2.1.2. PRODUCTS
7.2.1.3. STRENGTHS & CHALLENGES
7.2.2. PFIZER
7.2.2.1. COMPANY OVERVIEW
7.2.2.2. PRODUCTS
7.2.2.3. STRENGTHS & CHALLENGES
7.2.3. TEVA PHARMACEUTICAL INDUSTRIES LIMITED
7.2.3.1. COMPANY OVERVIEW
7.2.3.2. PRODUCTS
7.2.3.3. STRENGTHS & CHALLENGES
7.2.4. MUNDIPHARMA INTERNATIONAL
7.2.4.1. COMPANY OVERVIEW
7.2.4.2. PRODUCTS
7.2.4.3. STRENGTHS & CHALLENGES
7.2.5. HANMI PHARMACEUTICAL CO
7.2.5.1. COMPANY OVERVIEW
7.2.5.2. PRODUCTS
7.2.5.3. STRENGTHS & CHALLENGES

List of Tables

LIST OF TABLES
TABLE 1: MARKET SNAPSHOT — CANCER PAIN MANAGEMENT
TABLE 2: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY DRUG TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 3: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY DRUG TYPE, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 4: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY MORPHINE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 5: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY MORPHINE, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 6: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY DISEASE INDICATION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 7: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY DISEASE INDICATION, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 8: LIST OF MERGERS & ACQUISITIONS
TABLE 9: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 10: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 11: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

List of Figures

LIST OF FIGURES
FIGURE 1: KEY MARKET TRENDS
FIGURE 2: PORTER’S FIVE FORCES ANALYSIS
FIGURE 3: GROWTH PROSPECT MAPPING — SOUTH KOREA
FIGURE 4: VALUE CHAIN ANALYSIS
FIGURE 5: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, GROWTH POTENTIAL, BY DRUG TYPE, IN 2023
FIGURE 6: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY OPIOIDS, 2024-2032 (IN $ MILLION)
FIGURE 7: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY MORPHINE, 2024-2032 (IN $ MILLION)
FIGURE 8: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, GROWTH POTENTIAL, BY MORPHINE, IN 2023
FIGURE 9: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY FENTANYL, 2024-2032 (IN $ MILLION)
FIGURE 10: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY OTHER MORPHINES, 2024-2032 (IN $ MILLION)
FIGURE 11: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY NON-OPIOIDS, 2024-2032 (IN $ MILLION)
FIGURE 12: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY ACETAMINOPHEN, 2024-2032 (IN $ MILLION)
FIGURE 13: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2024-2032 (IN $ MILLION)
FIGURE 14: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY NERVE BLOCKERS, 2024-2032 (IN $ MILLION)
FIGURE 15: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, GROWTH POTENTIAL, BY DISEASE INDICATION, IN 2023
FIGURE 16: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY LUNG CANCER, 2024-2032 (IN $ MILLION)
FIGURE 17: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY COLORECTAL CANCER, 2024-2032 (IN $ MILLION)
FIGURE 18: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY BREAST CANCER, 2024-2032 (IN $ MILLION)
FIGURE 19: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY PROSTATE CANCER, 2024-2032 (IN $ MILLION)
FIGURE 20: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY BLOOD CANCER, 2024-2032 (IN $ MILLION)
FIGURE 21: SOUTH KOREA CANCER PAIN MANAGEMENT MARKET, BY OTHER DISEASE INDICATIONS, 2024-2032 (IN $ MILLION)

Inkwood Researchは広範な市場を対象にし、また主要地域/国別の市場調査レポートで世界中の企業に活用されているインドに本社をおく市場調査会社です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

世界市場レポート

地域別レポート

国別レポート

ご購入に関するご案内

価格・納期について

• 価格
  • 2023年7月より全レポートの価格が値上げされました。弊社ウェブサイトでは旧価格が掲載されているページもございますが、2023年6月以前に出版されたレポートにも値上げが適用されます。予めご了承ください。
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
    • 印刷不可設定のPDFです。
  • コーポレートライセンス
    • 同一企業および関連会社間人数無制限でレポートファイルをご共有可能です。
    • PDF（印刷可能）とExcelをご提供いたします。
• 納期
  • ご注文後3-4営業日以内

• 納品形態
  • Eメール

注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでのご注文をお待ちしております。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

Inkwood Research出版の市場調査レポートに関するご質問やサンプルページのご依頼等はいつでもお気軽にお問合せください。

Inkwood Research 出版レポート一覧